Abstract
Current pharmacologic treatments for a depressive episode in unipolar major depressive disorder (MDD) and bipolar depression are limited by low rates of remission. Residual symptoms include a persistent low mood and neurovegetative symptoms such as fatigue. The objective of this study was to examine the efficacy and tolerability of augmentation of first-line therapies with the novel stimulant-like agent modafinil in MDD and bipolar depression.
Original language | English |
---|---|
Article number | N/A |
Pages (from-to) | 1101-1107 |
Number of pages | 7 |
Journal | PRIMARY CARE COMPANION TO THE JOURNAL OF CLINICAL PSYCHIATRY |
Volume | 74 |
Issue number | 11 |
DOIs | |
Publication status | Published - Nov 2013 |